Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech
Fouad Namouni, a storied research exec who went from project leader on Opdivo and Yervoy to the top of the oncology research group at Bristol Myers Squibb, is joining the migration to biotech, picking up a new hat as president of R&D at Blueprint Medicines.
Once again, he’s headed into a toe-to-toe showdown with a rival pharma organization.
Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprint’s RET rival to Eli Lilly’s Retevmo, which got out in front with a May approval. Ironically, Lilly’s deal to buy into RET with its acquisition of Loxo also brought Josh Bilenker and his crew to the pharma giant, marking a rare career trajectory from a biotech into pharma, which has been bleeding talent for years now.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.